Recarbrio Europska Unija - hrvatski - EMA (European Medicines Agency)

recarbrio

merck sharp & dohme b.v.  - monohidrat Имипенем, циластатин natrija, relebactam monohidrat - Грамотрицательные bakterijske infekcije - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 i 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 i 5. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Mekinist Europska Unija - hrvatski - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. Немелкоклеточный rak pluća (НМРЛ)trametinib u kombinaciji s dabrafenib indiciran za liječenje odraslih bolesnika s preliminarnim non-mali raka pluća stanice s Браф mutacija v600 daleko .

Epirubicin Sandoz 2 mg/ml otopina za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

epirubicin sandoz 2 mg/ml otopina za injekciju/infuziju

sandoz d.o.o., maksimirska 120, zagreb - epirubicinklorid - otopina za injekciju/infuziju - 2 mg/ml - urbroj: jedan mililitar (ml) otopine sadrži 2 mg epirubicinklorida

HorStem Europska Unija - hrvatski - EMA (European Medicines Agency)

horstem

equicord s.l. - лошадиный krvi iz pupkovine мезенхимальных matičnih stanica - ostali lijekovi za poremećaje mišićno-koštanog sustava - konji - smanjenje hromost vezane uz blage do umjerene degenerativne bolesti zglobova (osteoartritis) u konja.

Mayzent Europska Unija - hrvatski - EMA (European Medicines Agency)

mayzent

novartis europharm limited  - siponimod фумаровая kiselina - multipla skleroza, Рецидивно-Ремиттирующее - selektivni imunosupresivi - mayzent indiciran za liječenje odraslih bolesnika sa sekundarno-прогрессирующим multiplom sklerozom (ВПРС) s aktivnim bolesti svjedoče recidiva ili značajke za vizualizaciju aktivnosti upalnog procesa.

Atectura Breezhaler Europska Unija - hrvatski - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Invokana Europska Unija - hrvatski - EMA (European Medicines Agency)

invokana

janssen-cilag international nv - canagliflozin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5.